Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis
Open Access
- 1 January 2026
- journal article
- review article
- Published by Wiley in Stem Cells International
- Vol. 2026 (1) , 2759804
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β‐cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP‐1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long‐term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β‐cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long‐term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance.Keywords
Funding Information
- Basic and Applied Basic Research Foundation of Guangdong Province (2023A1515012343)
- Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515220099)
This publication has 141 references indexed in Scilit:
- ISG15 Mediates Oxidative Stress Modulation in T2DM Patients by Directly Targeting PIK3R2BioFactors, 2026
- Epigenetic silencing of MSTN via m6A modification underlies the renoprotective effects of engineered MSC exosomes with RBM15 depletion in diabetic nephropathyFunctional & Integrative Genomics, 2025
- Differentiation to insulin-positive cells from human amnion epithelial cells using a pancreatic development mimicry protocolHistochemistry and Cell Biology, 2025
- Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome EditingSmall Science, 2024
- Mesenchymal stem cells (MSCs) and MSC‐derived exosomes in animal models of central nervous system diseases: Targeting the NLRP3 inflammasomeIUBMB Life, 2023
- Insulin-producing cell clusters derived from human gingival mesenchymal stem cells as a model for diabetes researchMolecular Biology Reports, 2022
- Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetesJournal of Extracellular Vesicles, 2021
- Human decellularized adipose matrix derived hydrogel assists mesenchymal stem cells delivery and accelerates chronic wound healingJournal of Biomedical Materials Research Part A, 2020
- Mesenchymal stem cells and ligand incorporation in biomimetic poly(ethylene glycol) hydrogels significantly improve insulin secretion from pancreatic isletsJournal of Tissue Engineering and Regenerative Medicine, 2014
- Large Scale Production of Stem Cells and Their Derivatives2009